Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Health Catalyst (HCAT) Capital Expenditures (2018 - 2025)

Health Catalyst's Capital Expenditures history spans 8 years, with the latest figure at $965000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 26.11% year-over-year to $965000.0; the TTM value through Dec 2025 reached $968000.0, down 40.1%, while the annual FY2025 figure was $968000.0, 40.1% down from the prior year.
  • Capital Expenditures reached $965000.0 in Q4 2025 per HCAT's latest filing, up from -$28000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $6.3 million in Q2 2021 to a low of -$7.6 million in Q3 2021.
  • Average Capital Expenditures over 5 years is $287050.0, with a median of $195000.0 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: crashed 1422.26% in 2021, then skyrocketed 9428.57% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $448000.0 in 2021, then surged by 354.69% to $2.0 million in 2022, then plummeted by 100.69% to -$14000.0 in 2023, then surged by 9428.57% to $1.3 million in 2024, then fell by 26.11% to $965000.0 in 2025.
  • Per Business Quant, the three most recent readings for HCAT's Capital Expenditures are $965000.0 (Q4 2025), -$28000.0 (Q3 2025), and -$157000.0 (Q2 2025).